6vkd

Crystal Structure of Inhibitor JNJ-36689282 in Complex with Prefusion RSV F Glycoprotein

spinqualitylabelsall models 6vkd, resolution 2.50Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 2.5Å Ligands: CL, R0P, SO4 Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Publication Abstract from PubMed Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection and is associated with significant morbidity and mortality. Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consist of supportive care. This publication covers the medicinal chemistry efforts resulting in the identification of JNJ-53718678, an orally bioavailable RSV inhibitor which showed to be efficacious in a phase 2a challenge study in healthy adult subjects and which is currently being evaluated in hospitalized infants and adults. Co-crystal structures of several new derivatives helped rationalizing some of the structure activity relationship (SAR) trends observed. Discovery of 3 ({5 Chloro-1 [3 (methylsulfonyl)propyl]-1H indol-2 yl}methyl)-1 (2,2,2 trifluoroethyl)-1,3 dihydro-2H imidazo[4,5-c]pyridin-2 one (JNJ-53718678), a potent and orally bioavailable fusion inhibitor of respiratory syncytial virus.,Vendeville S, Tahri A, Hu L, Demin S, Cooymans L, Vos A, Kwanten L, Van den Berg J, Battles M, McLellan J, Koul A, Raboisson P, Roymans D, Jonckers THM J Med Chem. 2020 May 14. doi: 10.1021/acs.jmedchem.0c00226. PMID:32407115 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA